Hospital

3D biofabrication models reflect increasing global awareness of the ethics of preclinical studies and an increased need for determining therapeutic efficacy differences.

Nick Ferreyros, managing director of policy, advocacy, and communications at the Community Oncology Alliance, discussed the Alliance’s efforts surrounding PBMs and 340B reform.

Retifanlimab-dlwr (Zynyz; Incyte) was granted FDA accelerated approval for metastatic or recurrent locally advanced Merkel cell carcinoma.

There is no single thing that can prevent all cancer risk, but there are 6 pillars of lifestyle that people can adopt to best prevent the disease.

Kandy Dunnigan, AAS, CPhT-Adv, a drug diversion analyst at Novant Health, discusses her role in the pharmacy.

Strong interprofessional team helps ensure safe transitions and minimize adverse events, medication errors

Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.

Blinded arms of the study will continue to evaluate the combination therapy with docetaxel vs docetaxel alone, Merck says.

Sandoz intends to launch the latest Humira biosimilar in the United States on July 1, 2023.

Educating patients, providers improves acceptance, trust as number of approvals, indications grows

The portfolio of oral oncology products has evolved over the past few years and so has the traditional model of distribution.

For the management of ovarian cancer, it has been observed in both cellular and animal models that curcumin suppresses cell proliferation and promotes apoptosis.

The COVID-19 pandemic marginally affected the negative mental health of women more than men, according to a new study.

Investigators estimate that the effectiveness was higher after 1 or 2 booster doses compared with the primary series alone.

Atea’s drug candidate is considered safe and effective against the viruses that cause COVID-19 and hepatitis C, according to new data presented at ICAR 2023.

Therapy effectively treats cells harboring HR deficiencies, including those of specific types of ovarian, breast cancers.

Most patients used nonproprietary drugs, which may contribute to the reduction of out-of-pocket costs for the treatment of invasive breast cancer.

Niraparib with abiraterone acetate could be the first dual-action tablet for patients with metastatic castration-resistant prostate cancer and BRCA mutations.

The kit is now approved in the US to select patients with metastatic prostate cancer who are candidates for the only FDA-approved PSMA-directed radioligand therapy.

Finerenone is a first in class nonsteroidal mineralocorticoid receptor antagonist indicated in adults with chronic kidney disease associated with type 2 diabetes mellitus.

Clostridioides difficile infection can have a significant impact on feelings of depression and anxiety, while worsening quality of life.

Liquid formulations of dabrafenib plus trametinib were also approved, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as 1 year of age.

Indya Wilson, MBA, CPhT, a pharmacy education support specialist at Novant Health Pharmacy Administration, discusses her role in the pharmacy and the benefits of alternative career paths for pharmacy technicians.

MenABCWY combination meets all 11 primary endpoints and shows that it is well tolerated, with a safety profile consistent with MenACWY (Menveo) and MenB (Bexsero).

The risk of long COVID-19 was no worse for patients who had Omicron after the wild-type virus than those just diagnosed with the wild-type.

Continued advancements in therapy may expand its use to larger patient population, though challenges remain

At 1 year, patients receiving chemotherapy regimens containing anthracyclines for lymphoma who took statins had an average ejection fraction that was 1.3% higher than those who took placebo.

Carlene Link, PharmD, BCPS, a clinical pharmacist, discusses career wellness.

Navigating insurance presents a challenge, but pharmacists improve stakeholder access and provide in-home care.

Trastuzumab deruxtecan was approved by the FDA for HER2-low breast cancer treatment in 2022 and could also benefit some patients with hormone receptor-positive or triple-negative disease.